Search Results

With the acquisition of the NGB (Next-Generation Bioprinting) high-resolution robotic bioprinting platform developed by Poietis the University of Barcelona becomes a reference in Tissue Engineering

Collaboration with Professor Philippe Menasché (PARCC Cardiovascular Research Center - Inserm - Université Paris Cité - UMR 970 and Cardiovascular Surgery Department, Georges Pompidou European Hospital)

The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine.

Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of NextGeneration Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a bioprinted skin substitute in collaboration with the Assistance Publique – Hôpitaux de Marseille.

Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues.

Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology

For more than four years, Poietis has been invested in the development of the NGB 4D bioprinting platform to meet the development and production needs of human biological tissues

Poietis, a leading company in 4D bioprinting solutions, today announces the commercial launch of Poieskin, its first bioprinted skin model.

Poietis along with Prometheus, a division of Skeletal Tissue Engineering at Leuven, Belgium, announced they had entered into a two-year Collaborative Research Agreement to develop high-precision 3D Bioprinting.

Poietis and Prometheus, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.